As I noted before, that review is ongoing. Certainly we have completed the review of the science and now it is in the final stages. The length of time that takes is dependent on a number of factors: the questions we pose to the company; how long they take to get back to the evaluators with those responses. And so, that dialogue with the company in the finalization of the review is ongoing, and I wanted to highlight again that it's complicated. We know we've got different regulators looking at the same data for AstraZeneca and making different decisions based on the science. That's why this is taking a little longer than the ones we have done before.
On February 22nd, 2021. See this statement in context.